Eloralintide: Side Effects

Safety Overview#

Eloralintide has been evaluated in two Phase 1 studies (148 participants total) and a 48-week Phase 2 trial (263 participants). The overall safety profile is characterized by dose-dependent gastrointestinal adverse events -- primarily nausea and fatigue -- that are generally mild to moderate and can be mitigated by slower dose escalation. No serious adverse events have been attributed to eloralintide across the clinical program.

The AMY1R-selective mechanism of eloralintide was specifically designed to reduce calcitonin receptor-mediated nausea, and preclinical comparisons with the non-selective cagrilintide support improved GI tolerability. However, at the highest doses, nausea rates remain clinically significant.

Adverse Events by Dose (Phase 2)#

Dose Escalation Impact#

The Phase 2 trial tested two dose-escalation arms (6-to-9 mg and 3-to-6-to-9 mg) in addition to fixed-dose arms. Key findings:

• Dose escalation reduced the peak incidence of nausea and fatigue compared with starting at the full 9 mg dose
• Adverse event rates at 1 mg and 3 mg were similar to placebo
• Slower titration allowed patients to build tolerance while still achieving substantial weight loss

Nausea#

Nausea is the most common adverse event and the primary tolerability-limiting factor:

• Mechanism: Likely mediated by activation of amylin receptors in the area postrema (chemoreceptor trigger zone)
• Onset: Typically occurs early in treatment or following dose increases
• Severity: Generally mild to moderate; severe nausea was uncommon
• Duration: Tends to diminish with continued treatment at a stable dose
• Management: Dose escalation, dose reduction if needed
• Selectivity advantage: Reduced calcitonin receptor activation may contribute to lower nausea compared with non-selective amylin analogs

Fatigue#

Fatigue was the second most common adverse event:

• Dose-dependent, ranging from 0% (1 mg) to 46% (9 mg)
• Generally mild to moderate
• May be related to reduced caloric intake and metabolic adaptation
• Often improves with continued treatment

Decreased Appetite#

• Reported in approximately 19% of Phase 1 participants
• Considered a pharmacological effect rather than a side effect
• Related to amylin's physiological role in satiety signaling
• Contributes to the weight-reducing effect of eloralintide

Serious Adverse Events#

• No serious adverse events have been attributed to eloralintide in published studies
• No deaths related to eloralintide have been reported
• The Phase 2 trial reported no clinically significant laboratory abnormalities, ECG changes, or vital sign changes attributed to treatment

Contraindications#

• Hypersensitivity: Known allergy to eloralintide or excipients
• Pregnancy: Not studied; weight loss during pregnancy is not recommended by any clinical guideline

Drug Interactions#

No clinically significant drug interactions have been identified. Eloralintide's amylin receptor pathway is mechanistically distinct from:

• GLP-1 receptor agonists (semaglutide, liraglutide)
• GLP-1/GIP agonists (tirzepatide)
• Insulin
• Oral antidiabetic medications

An ongoing Phase 2 study is evaluating combination use with tirzepatide.

Comparison of Side Effect Profiles#

Note: Cross-trial comparisons have significant limitations and should not be interpreted as direct equivalence.

Related Reading#

• Eloralintide overview and research guide
• Eloralintide dosing protocols
• Eloralintide risks and legal status